Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AVITA Medical (AVH) has received approval from the Federal Court of Australia for a scheme of arrangement to redomicile
  • The company intends to redomicile itself and its subsidiaries from Australia to the U.S.
  • Under the scheme, AVITA Therapeutics in the U.S. will become the Avita Group’s parent company
  • The company’s shares will be suspended from trading on the ASX from close of trading on June 23, 2020
  • AVITA Medical shares are 3.33 per cent in the red in early trade, priced at 43.5 cents each

AVITA Medical (AVH) has received approval from the Federal Court of Australia for a scheme of arrangement to redomicile.

The company intends to redomicile itself and its subsidiaries (Avita Group) from Australia to the U.S.

Under the scheme of arrangement, AVITA Therapeutics (Avita US) will become the parent company of Avita Group. Avita US is currently incorporated in the U.S. state of Delaware.

The company first announced its intention to redomicile on April 21, 2020. In the announcement, AVITA stated that it would list primarily on the Nasdaq, but would continue listing on the ASX in a secondary capacity.

The company partly attributed the move to an organisational change in direction. AVITA recently started focusing on developing new ways to treat burn injuries. The company believed that the Nasdaq would provide a larger market for that specific industry sector.

AVITA also estimated that redomiciling to the U.S. would save up to $400,000 a year in professional costs. Much of these costs were the result of having to report directly to two separate exchanges.

With the Court’s approval now in hand, AVITA can move forward with its plan to move to the U.S.

On June 23, 2020, the company plans to lodge a copy of the court orders with the Australian Securities and Investments Commission. Once ASIC registers those orders, the approved scheme will take effect.

AVITA’s company shares will be suspended from trading on the ASX, from close of trading on June 23, 2020. 

The company’s shares will be exchanged for CHESS depositary Interests (CDI’s) in Avita US’ Nasdaq shares. Specifically, all eligible ASX shareholders will receive five CHESS CDI’s for every 100 previously owned AVITA Medical shares.

The following day, Avita US will list on the Australian Securities Exchange. 

After the implementation date, which is slated for June 29, Avita US will also list on the Nasdaq, and commence trading its U.S. shares.

AVITA Medical shares are 3.33 per cent in the red in early trade, priced at 43.5 cents each at 10:54 am AEST.

AVH by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.